Your browser doesn't support javascript.
loading
Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease.
Fernández Zapata, Camila; Giacomello, Ginevra; Spruth, Eike J; Middeldorp, Jinte; Gallaccio, Gerardina; Dehlinger, Adeline; Dames, Claudia; Leman, Julia K H; van Dijk, Roland E; Meisel, Andreas; Schlickeiser, Stephan; Kunkel, Desiree; Hol, Elly M; Paul, Friedemann; Parr, Maria Kristina; Priller, Josef; Böttcher, Chotima.
Afiliação
  • Fernández Zapata C; Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, 13125, Germany.
  • Giacomello G; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany.
  • Spruth EJ; Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 10117, Germany.
  • Middeldorp J; Institute of Pharmacy, Freie Universität Berlin, Berlin, 14195, Germany.
  • Gallaccio G; Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 10117, Germany.
  • Dehlinger A; DZNE, Berlin, 10117, Germany.
  • Dames C; Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, 3584 CX, Utrecht, The Netherlands.
  • Leman JKH; Department of Neurobiology and Aging, Biomedical Primate Research Centre, 2288 GJ, Rijswijk, The Netherlands.
  • van Dijk RE; Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, 13125, Germany.
  • Meisel A; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany.
  • Schlickeiser S; Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 10117, Germany.
  • Kunkel D; Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, 13125, Germany.
  • Hol EM; Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, 13125, Germany.
  • Paul F; Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 10117, Germany.
  • Parr MK; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, 10117, Germany.
  • Priller J; Department of Neuropsychiatry and Laboratory of Molecular Psychiatry, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, 10117, Germany.
  • Böttcher C; Institute of Biology, Humboldt-Universität zu Berlin, Berlin, 10115, Germany.
Nat Commun ; 13(1): 7210, 2022 11 23.
Article em En | MEDLINE | ID: mdl-36418303
Myeloid cells are suggested as an important player in Alzheimer´s disease (AD). However, its continuum of phenotypic and functional changes across different body compartments and their use as a biomarker in AD remains elusive. Here, we perform multiple state-of-the-art analyses to phenotypically and metabolically characterize immune cells between peripheral blood (n = 117), cerebrospinal fluid (CSF, n = 117), choroid plexus (CP, n = 13) and brain parenchyma (n = 13). We find that CSF cells increase expression of markers involved in inflammation, phagocytosis, and metabolism. Changes in phenotype of myeloid cells from AD patients are more pronounced in CP and brain parenchyma and upon in vitro stimulation, suggesting that AD-myeloid cells are more vulnerable to environmental changes. Our findings underscore the importance of myeloid cells in AD and the detailed characterization across body compartments may serve as a resource for future studies focusing on the assessment of these cells as biomarkers in AD.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Idioma: En Ano de publicação: 2022 Tipo de documento: Article